Summary
NeuroEM Therapeutics aims to reverse Alzheimer’s cognitive decline with a non-invasive wearable headset. Their innovative product uses transcranial electromagnetic treatment with radio frequencies, avoiding the side effects of current drug-based therapies. They are in the midst of a $5 million Series A funding round, have started national trials, and received FDA clearance for direct-to-consumer sales. They are also seeking key hires and partnerships to accelerate progress.
Highlights
🧠 NeuroEM Therapeutics' wearable headset targets Alzheimer’s cognitive decline using non-invasive transcranial electromagnetic treatment with radio frequencies.
💰 The company is currently raising $5 million in Series A funding, having already closed $3.3 million.
🧪 Up to 10,000 participants are being enrolled in national trials to collect real-world data.
🏅 NeuroEM received FDA 513G clearance for launching their direct-to-consumer version, which brings them closer to broader impact.
🤝 Being part of the Alzheimer’s Moonshot Community has boosted their credibility, visibility, and collaborations with fellow innovators.
🚀 The company is hiring for a medtech product manager and research operations lead to speed up product development.
🔬 They are seeking to partner with a national Alzheimer's expert to elevate their clinical and scientific influence.
Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world’s biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is available to StartUp Health Members. If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit.
👉 Learn more and join today.
